Warning letter
Brower Enterprises: warning letter of Sep 9, 2013
FDA warning letter 394702 · Minneapolis District Office
Key facts
| Reference number | 394702 |
|---|---|
| Company | Brower Enterprises |
| Subject | CGMP/Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements/Adulterated |
| Issue date | Sep 9, 2013 |
| Posted date | Sep 9, 2013 |
| Issuing office | Minneapolis District Office |
| Product type | Food/Cosmetics |
| CFR sections cited | 101.4(g), 111, 111.55, 111.103, 111.105, 111.453, 111.503, 111.515, 111.520, 111.553, 111.560, 101.2(e) and 26 more |
| Inspection city | Canton |
| Inspection ZIP | 57013 |
| Inspection start date | Dec 4, 2012 |
| Letter on fda.gov | web.archive.org |
At a glance
- 10–99 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: